Skip to main content
Top
Published in: Intensive Care Medicine 9/2018

01-09-2018 | From the Inside

HES: time to change my mind?

Author: Guenther Frank

Published in: Intensive Care Medicine | Issue 9/2018

Login to get access

Excerpt

I very well remember the presentation of Konrad Reinhart at the ESICM Lives Congress 2011 in Berlin about the recommendations of the task force on colloid volume therapy in critically ill patients, which were later published in this journal [1]. I was a believer and the consumption of HES in my anesthesia department in Eisenstadt Austria went down to a minimum over the next year and we abandoned any synthetic colloid and stopped using HES, not only in the ICU but also in anesthesia and in emergency medicine including obstetrics and trauma care. Since this is a radical decision, I followed the discussion about HES very carefully over the last years. Large trials were carried out and published and heavily criticized. On December 19th, 2013, the European Medicines Agency published a decision of the European Commission that HES solutions must no longer be used to treat patients with sepsis or burn injuries or critically ill patients, because of an increased risk of kidney injury and mortality, but HES wiould be available in restricted patient populations. Manufacturers were forced to include contraindications and warnings in the drug information. Usage of HES further went down and the discussion cooled down. Now in January 2018, PRAC and EMA started a new initiative to suspend the licence of HES in the EU, and the discussion started again [2]. …
Literature
1.
go back to reference Reinhart K, Perner A, Sprung CL, Jaeschke R, Schortgen F, Johan Groeneveld AB, Beale R, Hartog CS (2012) Consensus statement of the ESICM task force on colloid volume therapy in critically ill patients. Intensive Care Med 38:368–383CrossRefPubMed Reinhart K, Perner A, Sprung CL, Jaeschke R, Schortgen F, Johan Groeneveld AB, Beale R, Hartog CS (2012) Consensus statement of the ESICM task force on colloid volume therapy in critically ill patients. Intensive Care Med 38:368–383CrossRefPubMed
2.
go back to reference Annane D, Fuchs-Buder T, Zoellner C, Kaukonen M, Scheeren TWL (2018) EMA recommendation to suspend HES is hazardous. Lancet 391:736–738CrossRefPubMed Annane D, Fuchs-Buder T, Zoellner C, Kaukonen M, Scheeren TWL (2018) EMA recommendation to suspend HES is hazardous. Lancet 391:736–738CrossRefPubMed
3.
go back to reference Joosten A, Delaporte A, Ickx B, Touihri K, Stany I, Barvais L, Van Obbergh L, Loi P, Rinehart J, Cannesson M, Van der Linden P (2018) Crystalloid versus colloid for intraoperative goal-directed fluid therapy using a closed-loop system: a randomized, double-blinded, controlled trial in major abdominal surgery. Anesthesiology 128:55–66CrossRefPubMed Joosten A, Delaporte A, Ickx B, Touihri K, Stany I, Barvais L, Van Obbergh L, Loi P, Rinehart J, Cannesson M, Van der Linden P (2018) Crystalloid versus colloid for intraoperative goal-directed fluid therapy using a closed-loop system: a randomized, double-blinded, controlled trial in major abdominal surgery. Anesthesiology 128:55–66CrossRefPubMed
4.
go back to reference Neuhaus W, Schick MA, Bruno RR, Schneiker B, Förster CY, Roewer N, Wunder C (2012) The effects of colloid solutions on renal proximal tubular cells in vitro. Anesth Analg 114:371–374CrossRefPubMed Neuhaus W, Schick MA, Bruno RR, Schneiker B, Förster CY, Roewer N, Wunder C (2012) The effects of colloid solutions on renal proximal tubular cells in vitro. Anesth Analg 114:371–374CrossRefPubMed
5.
go back to reference Schlimp CJ, Cadamuro J, Solomon C, Redl H, Schöchl H (2013) The effect of fibrinogen concentrate and factor XIII on thromboelastometry in 33% diluted blood with albumin, gelatine, hydroxyethyl starch or saline in vitro. Blood Transfus 11:510–517PubMedPubMedCentral Schlimp CJ, Cadamuro J, Solomon C, Redl H, Schöchl H (2013) The effect of fibrinogen concentrate and factor XIII on thromboelastometry in 33% diluted blood with albumin, gelatine, hydroxyethyl starch or saline in vitro. Blood Transfus 11:510–517PubMedPubMedCentral
6.
go back to reference Chappell D, Jacob M, Becker BF, Hofmann-Kiefer K, Conzen P, Rehm M (2008) Expedition glycocalyx. A newly discovered “Great Barrier Reef”. Anaesthesist 57:959–969CrossRefPubMed Chappell D, Jacob M, Becker BF, Hofmann-Kiefer K, Conzen P, Rehm M (2008) Expedition glycocalyx. A newly discovered “Great Barrier Reef”. Anaesthesist 57:959–969CrossRefPubMed
7.
go back to reference Schött U, Solomon C, Fries D, Bentzer P (2016) The endothelial glycocalyx and its disruption, protection and regeneration: a narrative review. Scand J Trauma Resusc Emerg Med 24:48CrossRefPubMedPubMedCentral Schött U, Solomon C, Fries D, Bentzer P (2016) The endothelial glycocalyx and its disruption, protection and regeneration: a narrative review. Scand J Trauma Resusc Emerg Med 24:48CrossRefPubMedPubMedCentral
Metadata
Title
HES: time to change my mind?
Author
Guenther Frank
Publication date
01-09-2018
Publisher
Springer Berlin Heidelberg
Published in
Intensive Care Medicine / Issue 9/2018
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-018-5124-x

Other articles of this Issue 9/2018

Intensive Care Medicine 9/2018 Go to the issue

Imaging in Intensive Care Medicine

Biphasic isolated systolic aortic regurgitation